JPRN-UMIN000041707尚未招募未知
The clinical study investigating the effect of pemafibrate administration on cardiac diastolic function in patients with type 2 diabetes - The effect of pemafibrate on cardiac diastolic function in patients with type 2 diabetes
Yamaguchi University, Graduate School of Medicine, Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Department of Bio-Signal Analysis0 个研究点目标入组 20 人开始时间: 2020年9月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 25years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Who has a history of fibrate exposure within 6 months. 2) Who suffers from atrial fibrillation. 3) Who is judged by the investigators to be inappropriate for this study.
研究者
相似试验
已完成
不适用
A clinical study to discover the involvement of periodontal disease with circulative diseases in Japan and Asian countriesCardiovascular diseases, Periodontal diseaseJPRN-UMIN000017027Advanced Clinical Sciense and Therapeutics, the University of Tokyo2,000
尚未招募
2 期
Ayurveda management of Chronic tonsillitis in childreCTRI/2020/08/027344SDM College of Ayurveda and Hospital
已完成
不适用
A Clinical study to evaluate the effects of factors during surgery to predict outcome and patient satisfaction in patients undergoing general surgery under anesthesiaCTRI/2020/01/022901Adichunchanagiri medical college250
进行中（未招募）
1 期
A Clinical Trial for Newly Diagnosed High Risk ER+/HER2– (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast CancerHigh-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast CancerMedDRA version: 20.1Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864EUCTR2017-004869-27-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,140
进行中（未招募）
1 期
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast CancerTriple-Negative Breast CancerEUCTR2016-001432-35-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.858